204 results about "Lipid bilayer" patented technology

The invention belongs to the technical field of preparation of anti-tumor drugs, and particularly relates to a coptis root exosome, an extraction method thereof and application of the coptis root exosome in tumor resistance. The coptis root exosome is extracted from coptis roots, the size of the coptis root exosome is 125nm-135nm, and the coptis root exosome is shaped like a vesicle with a lipid bilayer structure. The coptis root exosome has an excellent anti-tumor effect and can remarkably inhibit tumor growth, and the tumor growth inhibition effect is remarkably superior to that of a common extract berberine in coptis roots.

The invention relates to the field of biological medicine, in particular to a hair follicle targeted delivery system and hair growth and hair loss prevention cosmetics, the hair follicle targeted delivery system comprises: a lipid nanoparticle core which is internally loaded with a bioactive component with hair growth and hair loss prevention effects; the hair follicle targeting molecule can specifically recognize and bind to a receptor on the surface of a hair follicle cell; a targeting anchoring conjugate composed of a linker covalently linked to the hair follicle targeting molecule and an anchoring lipid; wherein the targeting anchoring conjugate is embedded into the lipid bilayer of the lipid nanoparticle core through the anchoring lipid, so that the hair follicle targeting molecule is displayed on the surface of the lipid nanoparticle core. According to the application, through an innovative targeted anchoring conjugate structure, the targeting property and enrichment efficiency of hair growth and hair loss prevention active ingredients on hair follicle tissues can be remarkably improved, and the effect that a medicine accurately acts on a focus part is ensured, so that the number of hair follicles at an alopecia areata modeling part can be remarkably increased.

The invention belongs to the technical field of cosmetics, and particularly relates to a lipidosome composite microemulsion sun-screening agent, a preparation method thereof and application of the lipidosome composite microemulsion sun-screening agent in cosmetics. According to the invention, by selecting specific chemical sun-screening agents for matching, full-wave-band ultraviolet protection is realized, and the sun-screening effect is improved; a specific solid lipid matrix is selected, a chemical sun-screening agent is dispersed in a lipid bilayer by using a coating technology, irritation caused by direct contact with skin is reduced, meanwhile, release of the sun-screening agent is delayed, long-acting sun-screening and light stability are improved, and a product formed by combining with a specific preparation method is smaller in particle size, more uniform in component distribution and higher in stability. Therefore, a uniform film layer is formed on the surface of the skin and is tightly attached to the skin, penetration of ultraviolet rays is reduced, and the skin feeling light effect and the film-forming property at high temperature are improved. The sun-screening agent disclosed by the invention has the advantages of efficient ultraviolet protection, excellent stability and good skin feeling, and a new technical scheme is provided for the field of sun-screening cosmetics.

The invention discloses a compound liposome, a freeze-dried powder injection as well as a preparation method and application of the freeze-dried powder injection. The compound lipidosome comprises a lipidosome membrane and an inner water phase encapsulated in the lipidosome membrane, the paclitaxel palmitate is encapsulated in a lipid bilayer of the liposome membrane; the gemcitabine or the salt thereof is encapsulated in the inner water phase; the compound liposome comprises the following raw materials: paclitaxel palmitate, lecithin, a polyethylene glycol derivative, gemcitabine or a salt thereof, an organic solvent and a buffer solution A; the molar ratio of the lecithin to the polyethylene glycol derivative is 1: (0.01-0.15). The compound liposome disclosed by the invention is relatively high in encapsulation efficiency (especially the encapsulation efficiency of PTX-PA is relatively good) and relatively high in safety, the preparation method is simple and easy to operate, the industrialization degree is high, and the prepared compound liposome has a relatively good long-circulation effect, a relatively good anti-tumor effect and good in-vivo tolerance.

The present disclosure provides methods for preparing a liposome composition. One of the methods includes the steps of: providing precursor liposomes encapsulating platinum-based precursors; and incubating the precursor liposomes with a salt solution to convert the platinum-based precursors to platinum-based drugs to form the liposome composition. The precursor liposomes are prepared by step of: hydrating the platinum-based drugs to form the platinum-based precursors; and adding the platinum-based precursors to a lipid bilayer vehicle to form the precursor liposomes. The liposome composition prepared by the methods shows improved encapsulation efficiency and enhanced drug loading capacity.

The invention relates to the technical field of biology, in particular to silymarin inclusion compound lipidosome and a preparation method and application thereof. The silymarin inclusion compound liposome is prepared from the following components in parts by weight: 10 to 48 parts of silymarin, 10 to 53 parts of phospholipid, 5 to 10 parts of Arabic gum and 25 to 70 parts of cyclodextrin. According to the invention, cyclodextrin and phospholipid are combined to form a double-drug-loading structure; on the basis, Arabic gum is used as a film-forming agent to form a protective film on the surface of the liposome, so that the stability of the system is further improved; the silymarin inclusion compound is encapsulated in a water phase in the liposome, and meanwhile, part of free silymarin is encapsulated in a lipid bilayer. According to the structure, the solubility and the encapsulation efficiency of the silymarin are remarkably improved, the liposome stability is enhanced, the drug release is effectively controlled, and the silymarin inclusion compound lipid is simple in preparation process and suitable for industrial production.

The present disclosure provides a method of identifying a tumor for immunotherapy. The method comprises culturing tumor cells obtained from a subject; exposing the tumor cells to nanoparticles comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer; and measuring interferon-alpha and interleukin 6 (and optionally Chemokine (C-C motif) ligands 4) produced by the tumor cells. A method of treating a subject with cancer also is provided. The method comprises culturing tumor cells from the subject; exposing the tumor cells to the nanoparticles; measuring interferon-alpha and interleukin 6 (and optionally Chemokine (C-C motif) ligands 4) produced by the tumor cells; and administering an immune checkpoint inhibitor to the subject. Any of the methods may also comprise measuring CXCL 10.

In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg / batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).

The invention relates to the technical field of medicines, in particular to application of lycium barbarum-derived extracellular vesicles in preparation of a medicine for treating acute kidney injury. The used extracellular vesicles derived from Chinese wolfberry fruits have a lipid bilayer membrane structure, are good in stability, free of remarkable toxicity, good in blood compatibility and high in-vivo safety after long-term intravenous injection, are used for preparing the medicine for treating the acute kidney injury, and can reduce apoptosis, inhibit rising of blood urea nitrogen and creatinine levels and relieve injury of kidney tissues; the invention further provides application of the extracellular vesicles derived from the Chinese wolfberry fruits in preparation of the medicine for treating the lung injury disease, the weight loss is relieved, lung tissue is protected, meanwhile, the pulmonary alveolar-capillary barrier can be repaired, and in addition, the medicine can be used for treating the lung injury disease. The invention also provides application of the extracellular vesicles derived from Chinese wolfberry fruits in preparation of nuclear transcription factor kappa B inhibitors and / or inhibition of apoptosis and / or repair of pulmonary alveolar capillary barriers.

Disclosed are newly designed polymeric compounds (lipid-polymer conjugates) useful for forming lipid bilayers and liposomes comprising them, lipid bilayers and liposomes formed thereby, and uses thereof. Also disclosed is a method of preparing a new design of a polymeric compound (lipid-polymer conjugate).

Embodiments of the present invention include methods of targeting acidosis (low pH) within the tumor microenvironment (TME) through the use of cathodic electrochemical reactions (CER). Low pH is oncogenic by supporting immunosuppression. Electrochemical reactions create local pH effects when a current passes through an electrolytic substrate such as biological tissue. Electrolysis has been used with electroporation (destabilization of the lipid bilayer via an applied electric potential) to increase cell death areas. However, the regulated increase of pH through only the cathode electrode has been ignored as a possible method to alleviate TME acidosis, which could provide substantial immunotherapeutic benefits. Here, ex vivo modeling shows that CERs can intentionally elevate pH to an anti-tumor level and that increased alkalinity promotes activation of naïve macrophages. Embodiments of the invention include pairing CER treatment protocols with existing electric field-based cancer therapies or use as a stand-alone therapy.

The invention discloses a recombinant collagen composite nano-liposome as well as a preparation method and application thereof. The composite nano-liposome provided by the invention comprises a liposome which is provided with a closed lipid bilayer molecular layer and a content encapsulated in the closed lipid bilayer molecular layer; and a polyquaternium-51 layer that encapsulates the liposome. A supramolecular assembly, phospholipid wrapping and polyquaternium-51 protective layer is formed on the surface of the protein through a hierarchical wrapping technology, and multiple technologies are superposed, so that the stability and the transdermal absorption effect of the protein and the lipidosome are remarkably improved.

The invention relates to the technical field of biological medicines, and discloses an alpha-ketoglutaric acid composite liposome as well as a preparation method and application thereof. Alpha-ketoglutaric acid is preliminarily entrapped by lecithin and cholesterol to prepare a basic liposome, and then enzymolysis silkworm pupa protein is introduced to the surface of the liposome, so that the enzymolysis silkworm pupa protein and a lipid bilayer are subjected to hydrophobic and hydrogen-bond interaction to form a protein-lipid composite layer, and the stability of a membrane structure is enhanced; and the positively charged arginine modified starch is further deposited on the surface of the liposome to form a polysaccharide-protein-lipid composite layer, so that the electrostatic locking of the negatively charged alpha-ketoglutaric acid is realized, and the encapsulation efficiency and the controlled release performance are further improved. The alpha-ketoglutaric acid composite liposome provided by the invention has the advantages of being high in stability, safe to eat, high in encapsulation efficiency, good in gastric acid resistance stability and the like, has a good slow release characteristic, and can be applied to the fields of sports nutritional supplements, antioxidant products or anti-aging products and the like.

The present application relates to a kind of robecoxib liposome and its preparation method and application, the preparation raw material of the robecoxib liposome includes phospholipid, cholesterol and robecoxib, and the robecoxib is encapsulated in lipid bilayer, and the robecoxib liposome of the present application improves the solubility of robecoxib, and has higher encapsulation efficiency and drug loading.

The invention provides a membrane-wrapped organelle-like system for directionally assembling membrane protein, which comprises a molecular framework and a closed lipid bilayer membrane wrapping the outer side of the molecular framework, the molecular framework is loaded with load molecules, the molecular framework directionally recombines the lipid bilayer membrane through a transmembrane region of the membrane protein, and the lipid bilayer membrane is loaded with the load molecules. The lipid bilayer membrane provides a barrier and protection for a molecular framework and loaded molecules, and the lipid bilayer membrane is provided with directional recognition molecules. According to the invention, a molecular framework wrapped by a lipid bilayer membrane is utilized, and a novel technology capable of simulating lipid vesicles of an organelle membrane framework is adopted, so that a brand-new directional delivery function on specific cells or specific organelles in the specific cells can be endowed. And oriented assembly of a membrane protein compound and effective loading of bioactive molecules are realized by using a process of chemically recombining the lipid bilayer membrane.

The Freestanding-Bilayer Microscope (FBM) utilizes scanned focused laser illumination that achieves precise illumination of fluorescent probes at a freestanding lipid bilayer formed in an experimental chamber positioned on the imaging platform of the FBM.

The invention provides a microfluidic device (100) for the formation of lipid bilayers, wherein the microfluidic device (100) comprises a first fluid inlet (111), a first fluid outlet (112), and a first microfluidic channel (110) configured to fluidically connect the first fluid inlet (111) and the first fluid outlet (112), wherein: (A) the first microfluidic channel (110) comprises a membrane formation section (200) having a membrane formation section axis (Emfs) of elongation, wherein the channel wall (115) at the membrane formation section (200) comprises a membrane formation wall section (215); (B) the membrane formation section (200) comprises a plurality of micropillars (210); (C) the plurality of micropillars (210) are configured in an n*m array parallel to the membrane formation section axis (Emfs) of elongation; wherein n is selected from the range of ≥1 and m is selected from the range of ≥2; wherein the n*m array is configured to define (i) n+1 elongated subchannels (110a,110b,110c...) within the first microfluidic channel (110) and (ii) per row of the n rows m-1 fluidic connection sections (105); wherein each of the plurality of micropillars (210) tapers in directions parallel to the membrane formation section axis (Emfs) of elongation towards respective adjacent micropillars (210); (D) the membrane formation wall section (215) is configured in a wave-like shape parallel to the membrane formation section axis (Emfs) of elongation.

Provided herein are compositions including lipids and copolymers in the form of a nanodisc assembly. The subject copolymers include monomer units of styrene and monomer units selected from acrylic acid and an acrylic acid derivative. In certain cases, the copolymer is a copolymer of styrene and acrylic acid. Also provided herein, is an aqueous solution comprising the subject composition. Also provided herein, are methods for producing a nanodisc assembly, including incubation of a lipid and a subject copolymer. Further provided herein, are methods for solubilizing a membrane protein in an aqueous solution, wherein the method includes forming a nanodisc assembly of a lipid bilayer having one or more membrane proteins embedded therein, and a subject copolymer. Also provided are methods of solubilizing a hydrophobic constituent in an aqueous solution, including forming a nanodisc assembly of a lipid, a hydrophobic constituent, and a subject copolymer.

The application provides a paclitaxel liposome injection and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The injection is prepared from the following injection-grade raw and auxiliary materials: paclitaxel, phospholipid, cholesterol, gamma-aminobutyric acid, potassium lactate, a buffer, a freeze-drying protective agent and water for injection. The gamma-aminobutyric acid and the potassium lactate are simultaneously added as the liposome membrane stabilizer, the two synergistically act, the compactness and the stability of the lipid bilayer are significantly enhanced, the paclitaxel encapsulation rate is improved, the drug leakage rate is reduced, and the long-term storage stability of the preparation is improved.

The disclosure relates to nanopore preparations with reduced concentrations of detergents including detergent-free preparations. The disclosure provides lipid nanoparticles (LNPs) comprising a lipid, saposin, and a nanopore, methods for producing such LNPs, as well as systems and methods for nanopore-based sequencing using such LNPs. The new nanopore preparation avoids the pitfalls of using detergent-based compositions, such as disrupting the interactions between a target molecule and a nanopore during sequencing, disruption of the lipid bilayer, and batch-to-batch variability in nanopore preparations.

This invention relates to the field of biomedicine, and more particularly to a hair follicle-targeted delivery system and a hair growth and anti-hair loss cosmetic. The hair follicle-targeted delivery system comprises: a lipid nanoparticle core loaded with bioactive ingredients having hair growth and anti-hair loss effects; a hair follicle-targeting molecule capable of specifically recognizing and binding to receptors on the surface of hair follicle cells; and a targeting and anchoring conjugate consisting of a linker covalently linked to the hair follicle-targeting molecule and an anchoring lipid. The targeting and anchoring conjugate is embedded in the lipid bilayer of the lipid nanoparticle core via the anchoring lipid, thereby exposing the hair follicle-targeting molecule on the surface of the lipid nanoparticle core. This application, through its innovative targeting and anchoring conjugate structure, can significantly improve the targeting and enrichment efficiency of the hair growth and anti-hair loss active ingredients on hair follicle tissue, ensuring precise drug action on the lesion site, thereby significantly increasing the number of hair follicles in the alopecia areata modeling area.

The invention discloses directional traditional Chinese medicine transdermal application equipment, and relates to the technical field of biomedical engineering industries, the directional traditional Chinese medicine transdermal application equipment comprises a transdermal application part, the transdermal application part comprises an administration part and an application assembly, and the administration part presses and conveys medicine to the application assembly; the application assembly comprises a middle plate and a plurality of pyramid-shaped silica gel micro-protrusions which are arranged on the surface of the middle plate and distributed in an array mode, the up-down telescopic component stretches out and draws back to transmit force to the drug delivery component so that the silica gel micro-protrusions can be pressed to be tightly attached to the surface layer of the skin, and through the tip pressure gradient design of the silica gel micro-protrusions, the application effect is good on the premise that the completeness of the skin is not damaged. A cuticle lipid bilayer is promoted to generate reversible shear slippage, a loose pore channel with gradient pore diameter distribution is formed, pore diameters capable of directionally introducing the medicine are formed, and compared with a traditional plaster, the transdermal efficiency of the medicine is improved by multiple times; compared with a microneedle technology, the risk of dermis injury is avoided, and zero-wound drug delivery is achieved.

The invention discloses a transrespiratory tract noninvasive drug delivery carrier and a preparation method and application thereof.The transrespiratory tract noninvasive drug delivery carrier comprises a lipid bimolecular layer and bioactive ingredients wrapped in the lipid bimolecular layer, and the lipid bimolecular layer comprises a liposome membrane and an enzyme responsive modification part embedded into the liposome membrane; the enzyme responsive modification part is a substrate polypeptide capable of being degraded by RTC-enz and polyethylene glycol connected with the substrate polypeptide. According to the invention, an enzyme-responsive modification part is introduced to the surface of a liposome membrane, so that efficient targeted disintegration of the liposome membrane is realized in pulmonary alveoli in an RTC-enz environment. Bioactive components carried by the liposome are uniformly distributed on the surface of a'gas-blood barrier 'in the pulmonary alveolus after the liposome is disintegrated, so that effective retention and uniform dispersion can be realized, and the condition that the liposome which cannot be disintegrated blocks a'gas-liquid' barrier on the surface of the pulmonary alveolus at the end of the respiratory tract is avoided; and potential toxicity caused by transfection of bioactive components carried by liposome which cannot be disintegrated into alveolar epithelial cells is also avoided.

The present invention relates to a coating material for drug-coated balloons, drug-coated balloons, and a coating solution for drug-coated balloons, as well as their preparation and application. The coating solution comprises an aqueous solvent and a plurality of core-shell structures dispersed in the aqueous solvent, each of which comprises a lipid bilayer coated with a drug. The core of the core-shell structure contains a plurality of drug-loaded particles, and the shell of the core-shell structure is a lipid bilayer with an outer hydrophilic group and an inner hydrophobic group. The drug-loaded particles comprise a plurality of drug-loaded nanocrystalline particles. The combination of nanocrystals and liposomes combines the advantages of these two types of drug carriers. The resulting lipid bilayer improves the solubility of poorly soluble drugs in drug-coated balloons, resulting in a high drug loading capacity, high drug carrier stability, and stable drug crystal form, allowing for controllable drug release rates.

The present invention relates to compositions comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of the nucleic acid in a lipid bilayer. The present invention further relates to said compositions for use in preventing and / or treating disease, particularly for use in preventing and / or treating cancer. The present invention further relates to methods for producing compositions comprising said nucleic acid-lipid particles.

Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for the treatment of infections caused by such microorganisms.

Diagnostic immunoassay reagent compositions are disclosed that include liposomes having analyte-specific binding element(s) associated therewith. In particular, the analyte-specific binding element(s) includes a transmembrane domain that anchors the element(s) in the lipid bilayer of the liposome; the analyte-specific binding element(s) further includes an extracellular / extra membrane domain that is exposed on the outer surface of the liposome and that comprises a domain that specifically binds to the target analyte. Also disclosed are kits, devices, and systems that contain the diagnostic immunoassay reagent compositions, as well as methods of producing and using the diagnostic immunoassay reagent compositions.

A computational system and method for digital modeling of cardiac cell membrane electrophysiology is disclosed. The system generates a digital model representing the cell membrane as a dielectric lipid bilayer comprising a capacitor element and a resistor element, where the resistor element is emulated by a plurality of ion channels. The system calculates cell membrane potential based on intracellular and extracellular concentrations of key ions, such as Na+, K+, Ca2+, and Cl-, using the Goldman-Hodgkin-Katz equation. Generation of cellular membrane action potentials is simulated by modeling the opening and closing of voltage-gated ion channels in response to triggering events. The model provides dynamic visualizations of the distinct phases of the action potential, including depolarization and repolarization, offering a high-fidelity tool for research and for enhancing the realism of training simulations in electrophysiology procedures.

A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.

The invention provides a microbial desalination system and device for saline-alkali soil improvement, and relates to the technical field of microbial washing and dewatering treatment.The microbial desalination system comprises a washing and dewatering treatment system which comprises a mechanical grid and a flocculation reaction tank and is used for removing suspended solids (silt and organic particles), reducing turbidity and improving subsequent microbial activity; and the microbial water purification system comprises a sequencing batch reactor and a microbial agent adding device, is equipped with an aeration system, and adsorbs or converts salt by using salt-tolerant microorganisms. According to the scheme, when the washing water is desalted through microorganisms, a PH regulator and glycerin are added into the washing water in the reaction tank firstly, the washing water with the high PH value is prevented from damaging a lipid bilayer structure of a microbial cell membrane by adjusting the PH value of the washing water, and therefore the extracellular environment is stabilized; and the compound can be actively absorbed into cells by microorganisms, the osmotic pressure in a high-salt environment is balanced, and cell dehydration is prevented.